New York City

Celdara Medical builds lasting partnerships with inventors and their institutions, and provides the developmental, financial, and business acumen to bridge the gap between discovery and clinical impact. Celdara has been in the New York City biotech community since 2014 and specializes in therapeutic development across all disease spaces. We invite inventors and technology professionals to reach out to us at any point for more information using the contact link below.



 Brandy Houser Site Head New York NY sm
Brandy Houser, Ph.D., Site Head

Brandy is responsible for operations of the New York/New Jersey office, as well as sourcing and vetting new pipeline assets. Previously, Brandy was an investment Associate at Brandon Capital Partners, an Australian venture capital firm and the Alliance Manager for Partners Healthcare, the corporate entity that oversees operations for the Massachusetts General Hospital and the Brigham and Women’s Hospital. During this time she managed technologies from both hospitals as well as programs for Pfizer’s Center for Therapeutic Innovation. She also helped to create the business and operations plan for The Human Translational Immunology Center at the Brigham and Women’s Hospital. 
Brandy received her Ph.D. in immunology from Harvard University under the guidance of Dr. Jack Strominger for the discovery of specialized macrophage subsets at the human maternal-fetal interface. During her graduate career she was also a commercialization fellow at Harvard Medical School.


Jean-Loup Romet Lemonne 

Jean-Loup Romet Lemonne, M.D., Site Consultant

Jean-Loup is Senior Advisor, Global Development at Institut Pasteur, in Paris, France working directly with the Institut Pasteur’s President on global development strategy. He coordinates selected strategic activities involving international locations. Previously Dr. Romet-Lemonne was for 17 years the President, CEO and Founder of IDM Pharma Inc. now part of Takeda Oncology, a biotech company developing anti-cancer immunotherapy. IDM’s first drug was approved in Europe in 2009 for the treatment osteosarcoma, a bone cancer that primarily affects children and young adolescents. During his academic and scientific training, Dr. Romet-Lemonne was a Senior Scientist in the Cancer Biology Department at the Harvard School of Public Health, Boston, and Associate Professor at the Medical School of Tours University in France. Dr. Romet-Lemonne received his MD from Tours University, completed business training at HEC in France, and executive training at Stanford University’s Graduate School of Business in Stanford, CA. He lives and works in New York City.

Audio Lecture Series


Celdara Medical operates out of the New York Blood Center in New York, NY.